RIGL(Rigel Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $149.24M | $120.24M | $116.88M | $179.28M | $294.28M |
| 毛利润 | $148.15M | $118.49M | $109.77M | $160.63M | $274.66M |
| 营业利润 | −$12.50M | −$55.55M | −$20.49M | $24.19M | $125.47M |
| 净利润 | −$17.91M | −$58.57M | −$25.09M | $17.48M | $367.02M |
| 经营现金流 | $5.88M | −$73.76M | −$5.74M | $31.47M | $75.66M |
| 自由现金流 | $5.25M | −$74.21M | — | — | — |
| 摊薄每股收益 | $-1.10 | $-3.44 | $-1.44 | $0.99 | $19.48 |